Intellia Therapeutics (NTLA) Long-Term Investments (2019 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Long-Term Investments of $10.1 million for Q1 2026, up 347.24% year-over-year from $2.3 million in Q1 2025, and down 11.33% quarter-over-quarter from $11.4 million in Q4 2025.
Intellia Therapeutics (NTLA) Long-Term Investments (2019 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Long-Term Investments for 7 consecutive years, with $10.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Investments rose 347.24% year-over-year to $10.1 million; the TTM figure through Mar 2026 stood at $10.1 million (up 347.24% YoY), while the FY2025 annual figure was $11.4 million, down 95.61% from the prior year.
- Long-Term Investments retreated to $10.1 million in Q1 2026 per NTLA's latest filing, from $11.4 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $260.2 million in Q4 2024 and bottomed at $2.3 million in Q1 2025.
- Historically, Long-Term Investments has averaged $66.5 million across 5 years, with a median of $32.6 million in 2022.
- Annual changes were most pronounced in 2024 — Long-Term Investments soared 2502.15% — and 2025, when it slumped 98.6%.
- Intellia Therapeutics' Long-Term Investments stood at $32.5 million in 2022, then slumped by 69.19% to $10.0 million in 2023, then jumped by 2502.15% to $260.2 million in 2024, then sank by 95.61% to $11.4 million in 2025, then retreated by 11.33% to $10.1 million in 2026.
- Business Quant data shows NTLA's Long-Term Investments at $10.1 million in Q1 2026, $11.4 million in Q4 2025, and $22.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 190.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 190.60 Mn |
| Mar 31, 2026 | 10.13 Mn |
| Dec 31, 2025 | 11.42 Mn |
| Sep 30, 2025 | 22.48 Mn |
| Jun 30, 2025 | 170.86 Mn |
| Mar 31, 2025 | 2.27 Mn |
| Dec 31, 2024 | 260.22 Mn |
| Sep 30, 2024 | 5.74 Mn |
| Jun 30, 2024 | 8.80 Mn |
| Mar 31, 2024 | 162.09 Mn |
| Dec 31, 2023 | 10.00 Mn |
| Sep 30, 2023 | 42.36 Mn |
| Jun 30, 2023 | 41.03 Mn |
| Mar 31, 2023 | 225.04 Mn |
| Dec 31, 2022 | 32.46 Mn |
| Sep 30, 2022 | 40.10 Mn |
| Jun 30, 2022 | 32.60 Mn |
| Mar 31, 2022 | 52.27 Mn |
| Dec 31, 2021 | 29.56 Mn |
| Sep 30, 2021 | 350.45 Mn |